We assessed the efficacy of anti–PD-1 combined with either anti-VEGF or lenvatinib in immune-competent murine models of local and disseminated melanoma and profiled tumor-infiltrating leukocytes and circulating cytokines/chemokines. This evidence concerns the gene VEGFA and melanoma.